DK1562985T3 - "Anvendelse af opløselige former af CD83 og nukleinsyrer, der koder for disse, til behandling eller forebyggelse af sygdomme" - Google Patents
"Anvendelse af opløselige former af CD83 og nukleinsyrer, der koder for disse, til behandling eller forebyggelse af sygdomme" Download PDFInfo
- Publication number
- DK1562985T3 DK1562985T3 DK03767573.3T DK03767573T DK1562985T3 DK 1562985 T3 DK1562985 T3 DK 1562985T3 DK 03767573 T DK03767573 T DK 03767573T DK 1562985 T3 DK1562985 T3 DK 1562985T3
- Authority
- DK
- Denmark
- Prior art keywords
- diseases
- prevention
- treatment
- nucleic acids
- acids encoding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02025851A EP1422241A1 (en) | 2002-11-19 | 2002-11-19 | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
PCT/EP2003/012941 WO2004046182A2 (en) | 2002-11-19 | 2003-11-19 | Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1562985T3 true DK1562985T3 (da) | 2015-04-13 |
Family
ID=32187165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03767573.3T DK1562985T3 (da) | 2002-11-19 | 2003-11-19 | "Anvendelse af opløselige former af CD83 og nukleinsyrer, der koder for disse, til behandling eller forebyggelse af sygdomme" |
Country Status (10)
Country | Link |
---|---|
US (3) | US7893200B2 (da) |
EP (5) | EP1422241A1 (da) |
JP (3) | JP4740595B2 (da) |
AU (1) | AU2003292045A1 (da) |
CA (2) | CA2847795C (da) |
DK (1) | DK1562985T3 (da) |
ES (2) | ES2413631T3 (da) |
HK (2) | HK1079220A1 (da) |
SI (1) | SI1562985T1 (da) |
WO (1) | WO2004046182A2 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1422241A1 (en) | 2002-11-19 | 2004-05-26 | Alexander Steinkasserer | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
US9102726B2 (en) | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
US7169898B2 (en) | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
CN101484461B (zh) * | 2006-08-18 | 2014-09-17 | 阿哥斯医疗公司 | Cd83在联合治疗中的用途 |
US8513208B2 (en) | 2008-02-28 | 2013-08-20 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
US20110182903A1 (en) * | 2008-05-23 | 2011-07-28 | Stephen Brand | Novel soluble cd83 polypeptides, formulations and methods of use |
EP2497498A4 (en) * | 2009-11-05 | 2013-04-17 | Univ Osaka | THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE |
CN104610452B (zh) * | 2015-01-27 | 2018-11-20 | 中国科学技术大学先进技术研究院 | 抗人cd83单克隆抗体及其制备、鉴定和应用 |
EP3318577A4 (en) | 2015-06-30 | 2019-01-23 | Osaka University | ANTIPLEXIN A1 AGONIST ANTIBODY |
CA3042683A1 (en) | 2016-11-07 | 2018-05-11 | Coimmune, Inc. | Bispecific antibodies that modulate tlr-4 signaling and uses thereof |
KR102679493B1 (ko) | 2017-01-31 | 2024-07-01 | 킴벌리-클라크 월드와이드, 인크. | 벤조산 에스테르를 포함하는 항균 조성물 및 이를 이용한 세균 생장 억제 방법 |
EP3895723A1 (en) | 2020-04-16 | 2021-10-20 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Scd83 for wound healing, hair growth, and skin and hair care |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5316920A (en) | 1992-04-17 | 1994-05-31 | Dana-Faber Cancer Institute, Inc. | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
US5710262A (en) | 1992-04-17 | 1998-01-20 | Dana-Faber Cancer Institute, Inc. | Nucleic acid encoding HB15 polypeptides |
WO1997029781A1 (en) * | 1996-02-15 | 1997-08-21 | Immunex Corporation | Methods and compositions for modulating an immune response |
DE69834334T2 (de) | 1997-08-26 | 2007-04-26 | Zymogenetics, Inc., Seattle | Für adipozyten spezifische protein homologe |
HUP0201009A2 (en) | 1999-05-07 | 2002-07-29 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
GB2370273A (en) | 2000-12-20 | 2002-06-26 | Viaxxel Biotech Gmbh | Compounds that affect CD83 expression |
AU2002240734A1 (en) * | 2001-10-18 | 2003-04-28 | Zlatko Ademovic | Repetitive motifs from salivary proline rich proteins, mucin and collagen |
EP1480598A4 (en) | 2001-11-21 | 2006-03-22 | Celltech R & D Inc | HANDLING CYTOKINE RATES USING CD83 GENE PRODUCTS |
US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
US6652537B2 (en) | 2001-12-12 | 2003-11-25 | C. R. Bard, Inc. | Articulating stone basket |
US20030219436A1 (en) | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
AU2002950779A0 (en) | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of immunomodulation |
EP1578366A4 (en) | 2002-10-09 | 2007-12-19 | Tolerrx Inc | MOLECULES PREFERABLY ASSOCIATED WITH EFFECTOR T CELLS OR REGULATORY T CELLS AND METHODS OF USE THEREOF |
EP1422241A1 (en) | 2002-11-19 | 2004-05-26 | Alexander Steinkasserer | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
US7169898B2 (en) | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
US9102726B2 (en) | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
US20110182903A1 (en) | 2008-05-23 | 2011-07-28 | Stephen Brand | Novel soluble cd83 polypeptides, formulations and methods of use |
-
2002
- 2002-11-19 EP EP02025851A patent/EP1422241A1/en not_active Withdrawn
-
2003
- 2003-11-19 EP EP15195041.7A patent/EP3031824A1/en not_active Withdrawn
- 2003-11-19 WO PCT/EP2003/012941 patent/WO2004046182A2/en active Application Filing
- 2003-11-19 EP EP03767573.3A patent/EP1562985B1/en not_active Expired - Lifetime
- 2003-11-19 CA CA2847795A patent/CA2847795C/en not_active Expired - Lifetime
- 2003-11-19 ES ES10188586T patent/ES2413631T3/es not_active Expired - Lifetime
- 2003-11-19 DK DK03767573.3T patent/DK1562985T3/da active
- 2003-11-19 ES ES03767573.3T patent/ES2534308T3/es not_active Expired - Lifetime
- 2003-11-19 SI SI200332422T patent/SI1562985T1/sl unknown
- 2003-11-19 US US10/535,522 patent/US7893200B2/en active Active
- 2003-11-19 EP EP10188586A patent/EP2345670B1/en not_active Expired - Lifetime
- 2003-11-19 AU AU2003292045A patent/AU2003292045A1/en not_active Abandoned
- 2003-11-19 JP JP2004552655A patent/JP4740595B2/ja not_active Expired - Lifetime
- 2003-11-19 CA CA2507373A patent/CA2507373C/en not_active Expired - Lifetime
- 2003-11-19 EP EP13189881.9A patent/EP2692733B1/en not_active Expired - Lifetime
-
2005
- 2005-12-09 HK HK05111319.6A patent/HK1079220A1/xx not_active IP Right Cessation
-
2011
- 2011-01-21 US US13/011,380 patent/US8759505B2/en active Active
- 2011-02-07 JP JP2011023799A patent/JP5557765B2/ja not_active Expired - Lifetime
-
2014
- 2014-04-24 JP JP2014090480A patent/JP5878584B2/ja not_active Expired - Lifetime
- 2014-06-17 US US14/306,712 patent/US9732140B2/en active Active
- 2014-08-04 HK HK14107931.1A patent/HK1194400A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2507373A1 (en) | 2004-06-03 |
ES2413631T3 (es) | 2013-07-17 |
SI1562985T1 (sl) | 2015-05-29 |
US20150065684A1 (en) | 2015-03-05 |
CA2847795C (en) | 2018-05-01 |
JP5557765B2 (ja) | 2014-07-23 |
EP2692733A1 (en) | 2014-02-05 |
EP1562985A2 (en) | 2005-08-17 |
JP4740595B2 (ja) | 2011-08-03 |
HK1194400A1 (zh) | 2014-10-17 |
EP1562985B1 (en) | 2015-01-07 |
JP2006523432A (ja) | 2006-10-19 |
WO2004046182A3 (en) | 2004-10-14 |
JP2014195455A (ja) | 2014-10-16 |
EP2692733B1 (en) | 2015-11-18 |
AU2003292045A1 (en) | 2004-06-15 |
EP2345670B1 (en) | 2013-03-20 |
HK1079220A1 (en) | 2006-03-31 |
EP1422241A1 (en) | 2004-05-26 |
CA2847795A1 (en) | 2004-06-03 |
US9732140B2 (en) | 2017-08-15 |
JP2011144177A (ja) | 2011-07-28 |
ES2534308T3 (es) | 2015-04-21 |
US8759505B2 (en) | 2014-06-24 |
AU2003292045A8 (en) | 2004-06-15 |
EP3031824A1 (en) | 2016-06-15 |
CA2507373C (en) | 2014-06-10 |
EP2345670A1 (en) | 2011-07-20 |
US20120015890A1 (en) | 2012-01-19 |
WO2004046182A2 (en) | 2004-06-03 |
JP5878584B2 (ja) | 2016-03-08 |
US20070167607A1 (en) | 2007-07-19 |
US7893200B2 (en) | 2011-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1427437T3 (da) | Oxyntomodulin til forebyggelse eller behandling af overvægt | |
IS8267A (is) | [1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa | |
IS7684A (is) | Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand | |
NO20044216L (no) | Partikkelmateriale med flere herdbare belegg og fremgangsmater for fremstilling og bruk derav. | |
ATE315938T1 (de) | 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen | |
NO20051503D0 (no) | Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme. | |
DE60230425D1 (de) | Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege | |
HK1079220A1 (en) | Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83 | |
IS7189A (is) | Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra | |
NO20044195L (no) | Biofosfoninsyrer for behandling og prevensjon av osteoprose | |
DK1487541T3 (da) | Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme | |
DK1342881T3 (da) | Opskummet syrebehandlingsvæske | |
DE50303749D1 (de) | Verfahren zur herstellung von phthalocyaninpigmentzubereitungen | |
NO20033854D0 (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
IS7163A (is) | Aðferðir til meðhöndlunar á lungnasjúkdómi | |
DK1372719T3 (da) | Nukleinsyre og tilsvarende protein betegnet 125P5C8, der er anvendelig i behandling og påvisning af cancer | |
DK1355668T3 (da) | Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom | |
DK1353912T3 (da) | 2-Arylimino-2,3-dihydrothiazolderivater, fremgangsmåderne til deres fremstilling og deres terapeutiske anvendelse | |
DK1461042T3 (da) | Anvendelse af desoxypeganin til behandling af klinisk depression | |
DE50211253D1 (de) | Verfahren zur Herstellung von Makrokapseln | |
NO20010345L (no) | Fremgangsmåte og anordning til behandling av gasser, samt anvendelse derav | |
DK1341758T3 (da) | Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme | |
DK1318142T3 (da) | t-butoxycarbonylaminoethylamin til syntese af PNA-monomerenheder, aminosyrederivater, mellemprodukter deraf og fremgangsmåder til fremstilling af disse | |
DE50302933D1 (de) | Beschichtungsmaterial, Verwendung desselben sowie Verfahren zur Aufbringung des Beschichtungsmaterials | |
DK1263423T3 (da) | Præparat til forebyggelse og/eller behandling af vaskulære sygdomme bestående af propionyl-L-carnitin og coenzym Q10 |